 Home > Medical News > Latest Medical News > Blockbuster drug with patent expiration in the next 10 years (12)-Disumab

Blockbuster drug with patent expiration in the next 10 years (12)-Disumab

 Last Update: 2021-09-04
 Source: Internet
 Author: User

Tags

chemical sales

anti cancer drugs

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Text | pick up shells

Amgen is no stranger to the costly patent cliff

In the absence of a large number of patent exclusivity losses in recent years, the company is expected to enter a growth phase driven by new drugs, including the migraine drug Aimovig (erenumab) and the newly approved anti-cancer drug Lumakras (sotorasib)

This situation may change at a later date, because the company's orthopedic drugs Prolia and Xgeva are expected to lose patent protection

Amgen’s annual report shows that denosumab’s patent is valid from 2021 to 2025

For Amgen, the loss of billions of dollars of exclusivity is a major event

Sales of Evenity ((romosozumab), a new osteoporosis drug launched in 2019, increased by 85% last year to 350 million U.

At the same time, in May of this year, Lumakras just received FDA approval for use in patients with KRAS G12C mutant non-small cell lung cancer

Attached table: Top 15 blockbuster drugs with patent expiration in the next 10 years

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.